The cause of renal anemia is multifactorial (Fisher 1980) . Although inadequate production of erythropoietin (EPO) by diseased kidneys is the main cause, inhibitors of erythropoiesis also play a significant role (Fukushima et al. 1986 ). Nowadays, we have recombinant human erythropoietin (rHuEPO) to treat renal anemia. Most patients respond well to rHuEPO (Winearls et al. 1986 ; Eschbach et al. 1987; Bommer et al. 1988 ; Urabe et al. 1988 ). Therefore, even if inhibitors are present in chronic renal failure (CRF), it is expected that they can be easily overcome by the use of rHuEPO . However, a few cases have been recognized as being resistant to rHuEPO therapy (Kuhn et al. 1988) , although the inhibitors of hematopoiesis in those cases were not identified. We have studied the inhibitory effects of ten uremic sera from the hemodialysis patients treated with rHuEPO on the formation of erythroid colonies (BFU-E and CFU-E) and granulocyte-macrophage colonies (CFU-GM) using normal human bone marrow cells as target cells. All ten patients responded to rHuEPO, although one case had a resistance to it for 4 months. We found the existence of CFU-E inhibitor in his serum, which is a new type of factor resistant to EPO treatment. If hemodialysis patients are treated with rHuEPO and are resistant to rHuEPO therapy, the inhibitors of hematopoiesis should also be considered.
MATERIALS AND METHODS

Subjects
Ten patients with CRF, who were placed on maintenance hemodialysis, were examined. All but one patient underwent dialysis three times a week. Only case 10 received twice weekly hemodialysis. They consisted of 5 males and 5 females, and their ages ranged from 25 to 72 years (mean+s.D., 50.7±18.1 years). Dialysis periods ranged from 18 to 170 months (93.9±49.7 months). All 10 patients were anemic. Their hematocrit levels were 20.4+1.4% (mean±s.E.). Underlying renal disorders included chronic glomerulonephritis (n = 5), chronic pyelonephritis (n =1), and other undetermined causes (n = 3). Case 8 was anephric, because of bilateral nephrectomy for renal stones due to cystinuria ( Table 1 ).
The administration of rHuEPO
Ten patients on maintenance hemodialysis were examined after informed consent was made (Table 1) . rHuEPO was administered to 10 patients as maintenance therapy. Except for case 9, preliminary rHuEPO administration had been made as a part of a Phase II study (Urabe et al. 1988) , and all patients responded well. After a given period of time, rHuEPO therapy was started again. The administration of rHuEPO to all patients was started with a dose of 3,000 U x 3/week for all patients except case 10. When the examinations were made, cases 5, 6, 7, and 8 were continued with the same dose for 9-10 weeks from the onset of rHuEPO administration. Cases 1, 2, 3, and 4 were given decreasing doses of 3,000 U X 2/week after 15-18 weeks. Only case 10 was continuously administered with 3,000 U x 2/ week for 17 weeks from the onset. Case 9 was administered with decreasing doses of 3,000 U>< 1/week after 26 weeks. rHuEPO was infused intravenously via an indwelling shunt immediately before the termination of each hemodialysis. The time of judgement on the effectiveness of rHuEPO was 8 weeks after the second administration of rHuEPO. The patients whose hematocrits increased above 5%, above 3% and up to 5%, and above -3% and up to 3% are defined as high responders, middle responders, and low responders, respectively. Moreover, good responders are defined as including high and middle responders (Tables 2 and 3 ).
Colony forming assays
Hemopoietic colony-forming cells were assayed in methylcellulose culture. For most of the experiments, erythroid colonies were assayed by culturing non-adherent marrow cells at a concentration of 105/ml in Iscove's modified Dulbecco medium (IMDM, Gibco, Grand Island, NY, USA), made semisolid with 0.96% methylcellulose, and supplemented with the following : 30% fetal calf serum (FCS, Hyclone, Logan, UT, USA), 1% deionized bovine serum albumin (Armour Pharmaceutical Company, Kankakee, IL, USA), 10-4 M 2-mercaptoethanol (Sigma Chemical Company, St. Louis, MO, USA), penicillin-streptomycin, and either 2 or 0.5 U/ml rHuEPO (Kirin-Amgen, Inc., Thousand Oaks, CA, USA). One ml volumes were cultured in 35 mm plastic tissue culture dishes (Lux', Miles Laboratories, Naperville, IL, USA) at 3TC in 5% CO2 in air. Erythroid colonies (derived from CFU-E) and bursts (from BFU-E) were enumerated with an inverted microscope after 7 and 14 days in culture, respectively. Aggregates of 8 or more hemoglobinized cells were scored as CFU-E-derived colonies. Erythroid bursts were identified as colonies of at least 200 hemoglobinized cells that were aggregates of two or more hemoglobinized subcolonies.
Granulocyte-macrophage colony-forming cells (CFU-GM) were assayed by culturing non-adherent marrow cells at a concentration of 105/ml in IMDM, made semisolid with 0.96% methylcellulose, and supplemented with 20% FCS, penicillin-streptomycin, and 10% CSF-"Chugai" (Chugai pharmaceutics, Tokyo). Granulocyte-macrophage colonies were identified by inverted microscopy as aggregates of 50 or more cells.
Assays for hemopoietic inhibitory and stimulatory activities in serum
The capacity of the hemodialysis patient (n =10) and control (n =20) serum to support or inhibit colony formation was examined by observing the effect of serum on colony growth from heterogenous marrow cells. CFU-E and BFU--E-derived colony growth in the presence of 10% test serum was compared with colony growth into which autologous serum, instead of test serum, was added. This was expressed as percent control colony growth (Fukushima et al. 1986 ). The less the percent control colony growth is, the stronger the inhibitory effect of the patient's serum on normal bone marrow cells is.
Similarly, CFU-GM-derived colony growth in the presence of 10% test serum was compared with colony growth into which autoserum, instead of test serum, was added. The blood type between bone marrow cells and test sera was matched.
Plasma EPO levels
Plasma EPO levels were measured by radioimmunoassay (RIA).
Assay for polyamines
Polyamines (spermine and spermidine) were measured in case 10 by high-performance liquid chromatography (HPLC).
Data analysis
All results are given as means+s.E. Student's t-test and F test, for the effect of repeated measures, were used to determine p values for statistical significance.
RESULTS
Each colony number formed in the absence of test serum was 327+67 for CFU-E (n=8), 66+10 for BFU-E (n=8), 98+22 for CFU-GM (n=7). We examined the effects of 18 to 20 normal sera on each colony formation of 8 normal human bone marrow cells. Not only test sera, but also one to three normal sera were added to normal human bone marrow cells simultaneously. Summing up the percentages of each colony growth, the normal range of each colony growth was determined. CFU-E, BFU-E, and CFU-GM colony growths were 104.4+ 3.1% (n = 20), 95.0 + 2.9% (n 19), 99.9 + 3.9% (n =18), respectively. The 95% confidence limits of these growths were from 74.0 to 134.7%, from 67.4 to 122.5%, and from 62.8% to 137.0%, respectively. Table 1 shows the data of all 10 patients in this study. Cases 1 through 8 were high responders. Case 9 was a middle responder. Case 10 was a low responder. No inhibitory effects of the sera on BFU-E and CFU-GM colony formations were recognized in any of the patients including case 10. However, the serum of case 10 who showed a resistance to rHuEPO therapy, had inhibitory effects on CFU-E formation. His percent control CFU-E growth was 70.9%, which was significantly lower than the normal range (p <0.05).
There was no serum inhibitor of CFU-E colony formation among the good responders. No EPO antibodies were detected in any of the patients. Plasma EPO titers of the 10 patients were 8.7+ 1.0 (n = 8), and 10.1±1.3 mU/ml (n =10) both before and after the administration of rHuEPO, respectively. The latter titers were significantly higher than the former (p <0.05). The EPO titers of the normal controls ranged from 8 to 30 mU/ml. The EPO level of case 10 was the greatest among our patients both before and after the administration of rHuEPO. Table 2 shows the effects of six uremic sera on CFU-E formation both before and after the administration of rHuEPO.
Five patients (cases 1, 5, 6, 7 and 9) had no inhibitory effects on CFU-E formation before the administration of rHuEPO. All of these patients were good responders. Case 5 was a forty-yearold woman. Her hematocrit was 10.3% before the induction of hemodialysis. At this time, the percent CFU-E colony growth was 6.0%, and the suppressive effect was the strongest among all our patients. But, it increased to 92.9% only 4 months after the onset of hemodialysis. In contrast, case 10 had a strong inhibitory effect on CFU-E colony formation even before the administration of rHuEPO. Fig. l shows the clinical course of a low responder of rHuEPO, i.e., of case 10. Before the administration of rHuEPO, the CFU-E colony growth was 46.5%, and was significantly lower than the normal range (p <0.01). The first administration of rHuEPO was 2 times per week and the dose was 6,000 U each time. A rapid recovery of hematocrit was noticed. The second administration of rHuEPO, which doses were decreased to 3,000 U x 2 per week, however, did not induce recovery of anemia for approximately 4 months and the percent CFU-E colony growth was 70.9% (p <0.05). After 4 months, anemia improved, although the percent CFU-E colony growth was 70.3% (p <0.05). At this time, the inhibitor of CFU-E still existed in his serum.
We examined Fe, UIBC, ferritin, PTH-C, fl2-microglobulin, aluminum, BUN, and creatinine in all 10 patients (Table 3) . None of them showed iron deficiency. PTH level was the highest in case 2, one of the good responders, while the aluminum concentration was higher in case 10, the low responder. Other labora- Cory data were not essentially different between both types of response. In only case 10, spermine and spermidine were measured. The former was 2.5 nmol/ml, and the latter was 8.7 nmol/ml. Both were within normal limits. Throughout the study course, the adverse effects of rH:uEPO including hypertension and thrombosis (Casati et al. 1987) were not observed.
DISCUSSION
It is generally accepted that a decreased production of EPO in CRF is the major pathogenetic mechanism involved in the development of renal anemia Eschbach 1989 ). In addition, many investigators believe that suppression of the bone marrow by uremic toxins also plays a significant role (Radtke et al. 1981 (Delwiche et al. 1986; Segal et al. 1988 ). Their reasoning is that the specificity of potential erythropoietic inhibitor can not be ascertained (Delwiche et al. 1986 ). However, Solangi et al. (1988) reported that erythropoietis-inhibitory activity was recently identified as being isolated and partially purified in a uremic patient. Moreover, it is reported that uremic monocyte-macrophages have a suppressive effect on BFU-E development which can be mediated by prostaglandin EZ (Lamperi and Carozzi 1987) . The administration of rHuEPO will give a good clue when one considers to test the role of inhibitors in vivo. If inhibitors play a significant role, they probably influence the responses caused by rHuEPO administration. It is reported that rHuEPO has been effective in virtually all anemic hemodialysis patients (Winearls et al. 1986; Eschbach et al. 1987; Bommer et al. 1988 ; Urabe et al. 1988; Eschbach 1989) . It is known, however, that effectiveness of rHuEPO varies among dialysis patients (Winearls et al. 1986; Casati et al. 1987; Eschbach et al. 1987) , and there are a few cases who have resisted to rHuEPO therapy (Kahn et al. 1988 ). Several conditions have been noted that interfere with or reduce the effectiveness of rHuEPO : osteitis fibrosa, iron deficiency, inflammatory states, and, possibly aluminum excess . Despite the highest value of serum PTH-C, case 2 was a good responder. Case 10 revealed a higher aluminum concentration in the present series. However, this level does not reach the range known as giving toxic effects on hematopoiesis (Mladenovic 1988) . His serum spermine and spermidine, which are regarded as one kind of the hemopoietic-inhibitory factors (Radtke et al. 1981) , were within the normal range. This case also has not had chronic inflammatory state or osteitis fibrosa. At the onset of the second administration of rHuEPO, the serum iron and ferritin concentrations in case 10 were 70 1cg/100 ml and 31 ng/ml, respectively, and 17 weeks later, they were 53 pg/100 ml and 106 ng/ml, respectively. Although case 10 did not have enough total-body iron stores, he should not be regarded as definite or presumptive iron deficiency anemia. Thus, it is highly probable that a delayed response to the lowered dose of rHuEPO Laboratory data in this case can be ascribed to the inhibitory effect of hematopoiesis, a new type of factor resistant to EPO treatment.
Since the initial treatment with the higher dose resulted in a prompt response, the inhibitory factor would have been overcome. Responses are reported to be dose-dependent over the range of between 45 and 1,500 U/kg/week (Eschbach et al. 1987) , therefore the dose of rHuEPO administered to case 10, which was 133 U/kg/week, should have been sufficient to correct anemia, but the dose of rHuEPO was considered not to be able to overcome the inhibitory factor of serum. Although the reason why the dose was effective after 4 months in spite of the presence of serum inhibitor was unclear, a "priming effect" was reported (Gutterman 1988) . With the administration of granulocytemacrophage colony-stimulating factor (GM-CSF), therapy had little effect during the first cycle, but with repeated cycle, a response was noted. In case 10, the priming effect of rHuEPO may have overcome the inhibitory effect of serum. The EPO titers of all 10 patients were within or less than the normal range. Because elevated EPO levels found in some uremic patients suggest the presence of a serum inhibitor (Caro and Erslev 1985) , the highest EPO values of case 10 will further support this possibility, although the EPO titers of case 10 were not higher than the normal values.
In conclusion, the present study has shown the presence of a new type of inhibitory factor of EPO action in uremic patients, although this factor can be overcome by increasing doses of rHuEPO.
Therefore, the initial determination of this factor may be helpful to set out minimal effective dose of EPO treatment.
